Roth Capital Resumes BioLineRx (BLRX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street rises on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Roth Reinstates BioLineRx (BLRX) at 'Buy'; Strong Pipeline Reinforces Upside Potential
July 2, 2014 9:27 AM EDTRoth Capital reinstates BioLineRx Ltd. (Nasdaq: BLRX) with a Buy rating and price target of $8.
Analust Joseph Pantginis issued the following commentary with the reinstatement, We believe BioLineRx is poised for growth based on a deep pipeline, risk mitigation through its early partnering business model, and partnering validation based on multiple partnerships already in hand. We believe BioLineRx has the ability to maintain a... More
